Literature DB >> 21521802

Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Seungjae Lee1, Velasco Cimica, Nandini Ramachandra, David Zagzag, Ganjam V Kalpana.   

Abstract

Rhabdoid tumors (RT) are aggressive pediatric malignancies with poor prognosis. INI1/hSNF5 is a component of the chromatin remodeling SWI/SNF complex and a tumor suppressor deleted in RT. Previous microarray studies indicated that reintroduction of INI1/hSNF5 into RT cells leads to repression of a high degree of mitotic genes including Aurora Kinase A (Aurora A, STK6). Here, we found that INI1/SNF5 represses Aurora A transcription in a cell-type-specific manner. INI1-mediated repression was observed in RT and normal cells but not in non-RT cell lines. Chromatin immunoprecipitation (ChIP) assay indicated that INI1/hSNF5 associates with Aurora A promoter in RT and normal cells but not in non-RT cells. Real-time PCR and immunohistochemical analyses of primary human and mouse RTs harboring mutations in INI1/hSNF5 gene indicated that Aurora A was overexpressed/derepressed in these tumor cells, confirming that INI1/hSNF5 represses Aurora A in vivo. Knockdown of Aurora A impaired cell growth, induced mitotic arrest and aberrant nuclear division leading to decreased survival, and increased cell death and caspase 3/7-mediated apoptosis in RT cells (but not in normal cells). These results indicated that Aurora A is a direct downstream target of INI1/hSNF5-mediated repression in RT cells and that loss of INI1/hSNF5 leads to aberrant overexpression of Aurora A in these tumors, which is required for their survival. We propose that a high degree of Aurora A expression may play a role in aggressive behavior of RTs and that targeting expression or activity of this gene is a novel therapeutic strategy for these tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521802     DOI: 10.1158/0008-5472.CAN-10-2167

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor.

Authors:  Dustin Tran; Sandra Camelo-Piragua; Avneesh Gupta; Kate Gowans; Patricia L Robertson; Rajen Mody; Carl Koschmann
Journal:  J Pediatr Hematol Oncol       Date:  2017-11       Impact factor: 1.289

3.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 4.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

Authors:  Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

Review 5.  Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Cancer Genet       Date:  2014-04-13

6.  Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Authors:  Sujatha Venkataraman; Irina Alimova; Tiffany Tello; Peter S Harris; Jeffrey A Knipstein; Andrew M Donson; Nicholas K Foreman; Arthur K Liu; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2012-01-15       Impact factor: 4.130

7.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

8.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.

Authors:  Cynthia Wetmore; James Boyett; Shaoyu Li; Tong Lin; Anne Bendel; Amar Gajjar; Brent A Orr
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

9.  Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.

Authors:  Francois Le Loarer; Lei Zhang; Christopher D Fletcher; Agnes Ribeiro; Samuel Singer; Antoine Italiano; Agnes Neuville; Aurélie Houlier; Frederic Chibon; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

Review 10.  The role of genetics in the establishment and maintenance of the epigenome.

Authors:  Covadonga Huidobro; Agustin F Fernandez; Mario F Fraga
Journal:  Cell Mol Life Sci       Date:  2013-03-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.